Metal-containing complexes have arisen as viable alternatives to organic molecules as therapeutic agents. Metal complexes possess a number of advantages compared to conventional carbon-based compounds, such as distinct geometries, interesting electronic properties, variable oxidation states and the ability to arrange different ligands around the metal centre in a precise fashion. Meanwhile, nitric oxide (NO) plays key roles in the regulation of angiogenesis, vascular permeability and inflammation. We herein report a novel cyclometalated rhodium(III) complex as an inhibitor of lipopolysaccharides (LPS)-induced NO production in RAW264.7 macrophages. Experiments suggested that the inhibition of NO production in cells by complex 1 was mediated through the down-regulation of nuclear factor-κB (NF-κB) activity. Furthermore, complex 1 inhibited angiogenesis in human umbilical vein endothelial cells (HUVECs) as revealed by an endothelial tube formation assay. This study demonstrates that kinetically inert rhodium(III) complexes may be potentially developed as effective anti-angiogenic agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jinorgbio.2014.06.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rhodium(III)-NSi Catalyzed Styrene Hydrosilylation: Evidence of the Hemilabile Character of NSi-type Ligands.
Chemistry
January 2025
Universidad de Zaragoza, Química Física, SPAIN.
The 18e saturated rhodium(III) species [Rh(H)(X)(κ2-NSitBu2)(bipyMe2)] (NSitBu2 = {4-methylpyridine-2-yloxy}ditertbutylsilyl; bipyMe2 = 4,4´-dimethylbipyridine) (X = Cl, 1; OTf, 2) have been prepared and characterized by NMR spectroscopy and in the case of 2 it has been possible to determine its solid-state structure by X-ray diffraction. Complex 1 has proven to be an effective catalyst precursor for the reaction of styrene derivatives with hydrosilanes in CD2Cl2. However, under catalytic conditions complex 2 decomposes.
View Article and Find Full Text PDFTriphenylphosphine-Modified Iridium, Rhodium, and Ruthenium Complexes to Achieve Enhanced Anticancer Selectivity by Targeting Mitochondria.
Inorg Chem
December 2024
Key Laboratory of Life-Organic Analysis of Shandong Province, Key Laboratory of Green Natural Products and Pharmaceutical Intermediates in Colleges and Universities of Shandong Province, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, P. R. China.
The incorporation of an organelle-targeting moiety into compounds has proven to be an effective strategy in the development of targeted anticancer drugs. We herein report the synthesis, characterization, and biological evaluation of novel triphenylphosphine-modified half-sandwich iridium, rhodium, and ruthenium complexes. The primary goal was to enhance anticancer selectivity through mitochondrial targeting.
View Article and Find Full Text PDFRhodium-catalyzed atropodivergent hydroamination of alkynes by leveraging two potential enantiodetermining steps.
Sci Adv
November 2024
Institute of Chemistry Frontier, School of Chemistry and Chemical Engineering, Shandong University, Qingdao 266237, China.
A pair of enantiomers is known to have different biological activities. Two catalysts with opposite chirality are nearly always required to deliver both enantiomeric products. In this work, chiral rhodium(III) cyclopentadienyl complexes are repurposed as efficient catalysts for enantiodivergent and atroposelective hydroamination of sterically hindered alkynes.
View Article and Find Full Text PDFBiological Evaluation of a Rhodium(III) Bipyridylsulfonamide Complex: Effects on Mitochondrial Dynamics and Cytoskeletal Remodeling in Breast Cancer Cells.
J Med Chem
December 2024
Faculty of Chemistry, Department of Bioinorganic Chemistry, University of Gdańsk, W. Stwosza 63, 80-308 Gdańsk, Poland.
Rhodium(III) complexes have gained attention for their anticancer potential. In this study, we investigated a rhodium(III) bipyridylsulfonamide complex () and its ligand () for their effects on breast cancer (SKBr3) and noncancerous mammary cells (HB2). Both compounds significantly reduced oxidative phosphorylation (OXPHOS) and mitochondrial function in SKBr3 cells while sparing HB2 cells.
View Article and Find Full Text PDFThe coordination chemistry and anticancer activity of organo-ruthenium(II), -iridium(III) and -rhodium(III) complexes with sulfonyl-substituted thiourea ligands.
Dalton Trans
January 2025
Chemistry and Applied Physics, Te Aka Mātuatua - School of Science, University of Waikato, Private Bag 3105, Hamilton 3240, New Zealand.
Some half-sandwich compounds with a variety of ligands and metal centres have shown promising anticancer activity. Herein we report a series of reactions between the sulfonylthiourea ligands -TolSONHC(S)NHPh, EtSONHC(S)NHPh and CHSONHC(S)NHPh and [(η--cymene)RuCl], [(η-arene)RuCl(PR)] (arene = benzene or -cymene), [Cp*MCl(PR)] or [Cp*RhCl] (M = Ir(III), Rh(III)), Cp* = η-pentamethylcyclopentadienyl, PR = triphenylphosphine (PPh), tris(2-cyanoethyl)phosphine (tcep) and 1,3,5-triaza-7-phosphaadamantane (pta) and their corresponding piano stool complexes. Single crystal X-ray diffraction structure determinations indicated that the resulting linkage isomer of the complex, , (coordination S,N placing the sulfonyl group near the coordination sphere) or (coordination S,N, placing the sulfonyl group away from the coordination sphere), is directly related to the steric bulk around the metal centre.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!